Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled,Safety, Immunogenicity, and Dose-escalation Study in Adults With and Without Latent Tuberculosis Infection in South Africa

NCT02933281 is registered in ClinicalTrials.gov with International AIDS Vaccine Initiative as lead sponsor.

NCT NCT02933281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02933281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled,Safety, Immunogenicity, and Dose-escalation Study in Adults With and Without Latent Tuberculosis Infection in South Africa
Lead sponsor
International AIDS Vaccine Initiative
Phase
Phase 1/2
Overall status
Completed
Start date
May 14, 2018
Completion date
September 5, 2021
Enrollment
144 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis